Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen operating margin
Operating margin is operating income as a percentage of revenue.
Repligen's operating margin for the twelve months ending Sep 30, 2026 was 2.3%. For fiscal 2025 it was 7.5%, against -5.5% the year before. The highest annual figure on record is 33.6% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.5% | +13.0 |
| FY2024 | Dec 31, 2024 | -5.5% | −13.1 |
| FY2023 | Dec 31, 2023 | 7.5% | −20.5 |
| FY2022 | Dec 31, 2022 | 28.0% | +3.1 |
| FY2021 | Dec 31, 2021 | 24.9% | +5.9 |
| FY2020 | Dec 31, 2020 | 19.1% | +5.7 |
| FY2019 | Dec 31, 2019 | 13.4% | −0.0 |
| FY2018 | Dec 31, 2018 | 13.4% | +3.5 |
| FY2017 | Dec 31, 2017 | 9.9% | −5.4 |
| FY2016 | Dec 31, 2016 | 15.3% | −1.2 |
| FY2015 | Dec 31, 2015 | 16.5% | −0.3 |
| FY2014 | Dec 31, 2014 | 16.8% | −16.7 |
| FY2013 | Dec 31, 2013 | 33.6% | +34.9 |
| FY2011 | Mar 31, 2011 | -1.4% | +26.1 |
| FY2010 | Mar 31, 2010 | -27.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -14.1% | −23.0 |
| Q2 FY2026 | Jun 30, 2026 | 6.8% | −0.8 |
| Q1 FY2026 | Mar 31, 2026 | 8.2% | +4.3 |
| Q4 FY2025 | Dec 31, 2025 | 9.0% | +30.8 |
| Q3 FY2025 | Sep 30, 2025 | 8.9% | +14.0 |
| Q2 FY2025 | Jun 30, 2025 | 7.6% | +4.2 |
| Q1 FY2025 | Mar 31, 2025 | 3.9% | +1.4 |
| Q4 FY2024 | Dec 31, 2024 | -21.8% | −27.7 |
| Q3 FY2024 | Sep 30, 2024 | -5.1% | −8.4 |
| Q2 FY2024 | Jun 30, 2024 | 3.4% | −8.7 |
| Q1 FY2024 | Mar 31, 2024 | 2.4% | −5.9 |
| Q4 FY2023 | Dec 31, 2023 | 5.9% | −20.2 |
| Q3 FY2023 | Sep 30, 2023 | 3.3% | −22.9 |
| Q2 FY2023 | Jun 30, 2023 | 12.1% | −18.3 |
| Q1 FY2023 | Mar 31, 2023 | 8.4% | −20.7 |
| Q4 FY2022 | Dec 31, 2022 | 26.1% | +6.1 |
| Q3 FY2022 | Sep 30, 2022 | 26.2% | +0.9 |
| Q2 FY2022 | Jun 30, 2022 | 30.4% | +0.8 |
| Q1 FY2022 | Mar 31, 2022 | 29.1% | +3.6 |
| Q4 FY2021 | Dec 31, 2021 | 20.1% | +4.0 |
| Q3 FY2021 | Sep 30, 2021 | 25.4% | +3.1 |
| Q2 FY2021 | Jun 30, 2021 | 29.6% | +7.3 |
| Q1 FY2021 | Mar 31, 2021 | 25.5% | +9.8 |
| Q4 FY2020 | Dec 31, 2020 | 16.0% | +7.5 |
| Q3 FY2020 | Sep 30, 2020 | 22.3% | +10.8 |
| Q2 FY2020 | Jun 30, 2020 | 22.3% | +6.7 |
| Q1 FY2020 | Mar 31, 2020 | 15.6% | −2.8 |
| Q4 FY2019 | Dec 31, 2019 | 8.5% | −6.6 |
| Q3 FY2019 | Sep 30, 2019 | 11.5% | −4.5 |
| Q2 FY2019 | Jun 30, 2019 | 15.6% | +6.7 |
| Q1 FY2019 | Mar 31, 2019 | 18.4% | +5.1 |
| Q4 FY2018 | Dec 31, 2018 | 15.1% | +7.3 |
| Q3 FY2018 | Sep 30, 2018 | 15.9% | +17.0 |
| Q2 FY2018 | Jun 30, 2018 | 9.0% | −7.9 |
| Q1 FY2018 | Mar 31, 2018 | 13.3% | −5.2 |
| Q4 FY2017 | Dec 31, 2017 | 7.8% | −3.5 |
| Q3 FY2017 | Sep 30, 2017 | -1.1% | – |
| Q2 FY2017 | Jun 30, 2017 | 16.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 18.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 11.3% | – |
See a number that looks wrong?